---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-017070"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2026-05-14T20:23:47+00:00"
generated_at: "2026-05-14T20:25:23.450067+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GeoVax Q1 2026 net loss $5.3M; cash $1.3M; advances GEO-MVA Phase 3

## Summary
- Net loss of $5.3M for Q1 2026 vs $5.4M in Q1 2025; no revenue vs $1.6M prior (BARDA contract terminated).
- Cash $1.3M at March 31, 2026, down from $3.1M at Dec 31, 2025.
- Phase 3 immunobridging study for GEO-MVA (mpox/smallpox) planned under EMA-aligned expedited pathway; enrollment ~500.
- Completed cGMP manufacturing and fill/finish; CRO selected for trial initiation.
- Exclusive license from Emory for Gedeptin in combination with immune checkpoint inhibitors.

## SEC filing metadata
- accession: 0001437749-26-017070
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2026-05-14T20:23:47+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774926017070/0001437749-26-017070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774926017070/govx20260513_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-017070
- JSON: https://secwatch.observer/filing/0001437749-26-017070.json
- Plain text: https://secwatch.observer/filing/0001437749-26-017070.txt

## Key facts
- Earnings Releases
  GeoVax Labs, Inc. reported the quarter ended March 31, 2026 results: net income $5.3 million.
  - Period: the quarter ended March 31, 2026
  - Net income: $5.3 million
  - Result: reported results
  source text: Net loss for the three months ended March 31, 2026, was $5.3 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/832489/000143774926017070/0001437749-26-017070-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.